论文部分内容阅读
目的探讨重组人脑利钠肽、米力农分别联合硝普钠治疗难治性心力衰竭临床效果。方法64例难治性心カ衰竭患者,随机分为A、B两组,各32例。A组患者予以重组人脑利钠肽联合硝普钠治疗,B组患者予以米力农联合硝普钠治疗,比较两组治疗效果。结果 A组治疗总有效率为93.8%,高于B组的75.0%,差异有统计学意义(χ~2=4.3,P=0.04<0.05)。治疗后,A组每搏输出量、心输出量、左室射血分数均优于B组,差异具有统计学意义(t=6.9、2.1、2.6,P<0.05)。A组不良反应发生率为12.5%,与B组的15.6%比较差异无统计学意义(P>0.05)。结论相较于米力农联合硝普钠,重组人脑利钠肽联合硝普钠治疗难治性心力衰竭的效果更佳。
Objective To investigate the clinical effect of recombinant human brain natriuretic peptide and milrinone combined with sodium nitroprusside in the treatment of refractory heart failure. Methods 64 cases of refractory heart failure patients were randomly divided into A and B groups, 32 cases in each. Patients in group A were treated with recombinant human brain natriuretic peptide and sodium nitroprusside. Patients in group B were treated with milrinone and sodium nitroprusside. The therapeutic effects were compared between the two groups. Results The total effective rate of treatment in group A was 93.8%, which was higher than that in group B (75.0%) (χ ~ 2 = 4.3, P = 0.04 <0.05). After treatment, the stroke volume, cardiac output and left ventricular ejection fraction in group A were better than those in group B, the difference was statistically significant (t = 6.9,2.1,2.6, P <0.05). The incidence of adverse reactions in group A was 12.5%, which was not significantly different from 15.6% in group B (P> 0.05). Conclusion Compared with Milrinone combined with sodium nitroprusside, recombinant human brain natriuretic peptide combined with sodium nitroprusside is more effective in treating refractory heart failure.